nystatin-a1 and Vaginal-Diseases

Topics: Adult; Candidiasis; Clinical Laboratory Techniques; Diagnosis, Differential; Female; Haemophilus Infections; Humans; Metronidazole; Nystatin; Recurrence; Sulfonamides; Trichomonas Vaginitis; Vaginal Diseases; Vaginitis; Vulvovaginitis

The aim of this study was to evaluate how konjac glucomannan hydrolysates (GMH) could support the healthy re-colonisation of vaginal microflora post infections. A total of 26 female patients (12 controls and 14 treatments) aged 18 to 25 suffering from vaginal infection were recruited for this study. Patients were assigned randomly into two groups to receive a standard antifungal treatment or a standard antifungal treatment plus pessary capsules containing 200 mg GMH (twice a week for thirty days). Patients were assessed on day zero, sixteen and thirty of the trial. Several parameters were determined including yeast and bacterial counts, the KOH test, pH, Gram staining and wet mount microscopic observations. The results showed that the counts of Candida were diminished completely with antifungal treatment for both groups. However, the total bacterial counts increased with time in the GMH pessary group unlike the control. The normalised average KOH scores were reduced sharply with time in both groups although in the control group scores started to increase after sixteen days. The normalised average white blood cell scores also decreased with time for both groups. Epithelial cell scores decreased only for the GMH pessary group while clue cells and yeast-like fungi decreased with time for both control and GMH pessary groups. These results indicate the improvement of vaginal health recovery (post antifungal treatment for Candida infection) and especially the presence of healthy microflora due to the introduction of GMH in the vagina. The data indicate that it would be worth examining further the health benefits of GMH in a vaginal health format with a view to employing the material as a prophylactic or therapeutic agent. It provides an alternative approach to reducing vaginal infections and promoting consumer health.

Topics: Adolescent; Adult; Antifungal Agents; Candida; Candidiasis, Vulvovaginal; Epithelial Cells; Female; Humans; Leukocyte Count; Mannans; Metagenome; Nystatin; Pessaries; Phytotherapy; Plant Extracts; Vagina; Vaginal Diseases; Young Adult

The dose-effect relationship of nifuratel (CAS 4936-47-4) + nystatin (CAS 1400-61-9, CAS 34786-70-4) (Macmiror Complex) in topical treatment of vulvo-vaginitis was studied.. Sixty patients with Trichomoniasis and/or Candidiasis were randomized to: 1) nifuratel 125 mg/nystatin 50000 IU, 2) nifuratel 250 mg/nystatin 100000 IU, 3) nifuratel 500 mg/nystatin 200000 IU. Undistinguishable ovules were intravaginally applied qd for 10 days. The dose-effect relationship was assessed by ANCOVA.. After 5 days the microbiological cure rate occurred in 10% of patients in the least dose, in 40% in the middle dose and in 85% in the highest dose group (P = 0.000). After 10 days of treatment, the microbiological cure rate increased to 45%, 84%, and 95%, respectively (P = 0.007). Clinical signs and symptoms gradually disappeared in a dose- and time-dependent manner. No relapse has been observed after 10 day-follow up on 46 patients.. The results confirmed a linear relationship between nifuratel + nystatin dose and effect. The least effective dose was nifuratel 250 mg + nystatin 100,000 IU once daily for 5 days and the best dose in terms of risk/benefit ratio was nifuratel 500 mg + nystatin 200,000 IU once daily for 5 days.

Topics: Adolescent; Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Middle Aged; Mycoses; Nifuratel; Nystatin; Treatment Outcome; Trichomonas Vaginitis; Vaginal Diseases

115 women, distributed in 20 centres, were included in a randomized study designed to assess the efficacy of Polygynax in preventing vaginal infections in women at risk, at the start of pregnancy. Polygynax proved to be markedly effective since only 9.6% of the patients in the Polygynax group had a vaginal infection, in contrast to 42.6% of the patients in the control group. This result is highly significant (p less than 0.0001) and confirms the advantage attached to the use of Polygynax when a first line treatment involving the use of several drugs in combination is indicated.

Topics: Adult; Arsenicals; Bacterial Infections; Clinical Trials as Topic; Drug Combinations; Drug Evaluation; Female; Humans; Multicenter Studies as Topic; Neomycin; Nystatin; Polymyxins; Pregnancy; Pregnancy Complications, Infectious; Random Allocation; Uterine Cervical Diseases; Vaginal Diseases

Topics: Candida albicans; Cytosine; Drug Evaluation; Female; Flucytosine; Humans; Mycoses; Nystatin; Vaginal Diseases

Nystatin G has proved to be an excellent antimycotic in suppository form, its concentration of active principle being 200,000 I.U. Mycoses were brought under complete control in 88 per cent of 75 patients by one single cycle of treatment, during which one suppository was inserted daily over ten consecutive days. Primary therapy failed in twelve per cent. Most of those patients had been using hormonal contraceptives over many years or were pregnant. Full therapeutic effect, basically, depends on successful treatment of the rectum on treatment of the partner.

Topics: Candida; Candidiasis, Vulvovaginal; Female; Humans; Mycoses; Nystatin; Pregnancy; Pregnancy Complications, Infectious; Vaginal Diseases

The activity of rapamycin, a new anti-Candida antibiotic, was not affected by pH values between 6 and 8; at pH 4, however, activity was abolished. The MIC of rapamycin did not vary drastically with the size of inoculum: a ten-fold dilution of the inoculum reduced the MIC only two-fold. Serum binding was extensive. Serum levels obtained in mice were higher on subcutaneous injection than with oral administration. Dogs absorbed rapamycin after oral administration. Rapamycin cured systemic candidosis in mice: PD50 s.c. was 9.5 mg/kg: PD50 p.o. was 11 mg/kg. In the same experimental infections amphotericin B and nystatin exhibited PD50 values of less than 0.25 mg and greater than 4,000 units/kg respectively. Rapamycin and amphotericin B, administered at 1, 4 and 24 hours after infection, gave approximately the same percent survival after 30 days of observation. When the above treatment was extended by an additional daily treatment for 6 days, rapamycin by the subcutaneous route yielded a higher percentage of survival than either rapamycin or amphotericin B, administered orally, after a 30-day observation period. Vaginal candidosis in female rats was treated efficiently (91% cure) by rapamycin administered orally. No increase of resistance of C. albicans was observed during treatment.

Topics: Amphotericin B; Animals; Antifungal Agents; Biological Availability; Candidiasis; Dogs; Female; Hydrogen-Ion Concentration; Male; Mice; Nystatin; Polyenes; Rats; Time Factors; Vaginal Diseases

A positive microbiological evidence could be obtained 54 times from the smear of the exterior genitals of 80 women suffering from complaints that were caused by urethritis, criteria of the examinations being sterile catheter specimen, negative cystoscopical findings, and missing indications to anatomical changes in the urethral region. Cytological examinations of these cases with regard to the vaginal epithelium had the following results:Group I:6 times; group II: 37 times; group IIW:8 times; group IIId: once; group IVa:twice. The cytological tests were carried out according to the method of papanicolaou as modified by Soost. Furthermore, we could state the following degrees of purity: Degree I: 8 times; degree II:16 times; degree III: 30 times. The cytological examinations of the urethral epithelium demonstrated, in 52 cases, an increased appearance of "nude" completely exposed epithelial cell nuclei--a fact corresponding to a degenerative autolysis (according to Wied). In the 26 women with missing atypical germ flora within the region of the exterior genitals, exclusively groups I (according to Papanicolaou and Soost) and degrees of purity I were stated. These persons also demonstrated remarkably grave psychical disturbances, especially in the intimate regions. In the cases of positive microbiological evidence, the following measures have proved satisfactory: Vaginal hygienization combined with a directly aimed antibacterial therapy, and the prescription of preparations containing lactic acid. A transitory discontinuation of contraceptives is being discussed. Our examination results are emphasizing the necessity of an analysis of the germ flora in cases of complaints arising from urethritis. Also psychical disturbances must be taken into consideration in cases of missing urological and gynaecological criteria of evidence.

Topics: Candidiasis, Vulvovaginal; Cervix Uteri; Chronic Disease; Female; Humans; Male; Metronidazole; Mycoplasma Infections; Nystatin; Psychophysiologic Disorders; Tetracycline; Trichomonas Vaginitis; Urethra; Urethritis; Vagina; Vaginal Diseases

14 women with a history of taking a combined oral contraceptive (norethynodrel plus mestranol) were studied and were found to have vaginal candidosis which commenced after an average period of 9 months from start of contraceptive therapy. 4 sexual contacts (men) of those women taking the pill were also discovered to have vaginal candidosis; they had presented with candidal balanoposthitis. 4 other men had clinical manifestations suggestive of balanoposthitis caused by hypersensitivity to the candidosis of their sexual partners. Nystatin was a satisfactory treatment in most cases; however, 2 women had to stop using the pill because of frequent relapses of yeast infections.

Topics: Balanitis; Candidiasis; Contraceptives, Oral; Female; Humans; Male; Mestranol; Norethynodrel; Nystatin; Suppositories; Vaginal Diseases

Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Candidiasis; Disease; Female; Humans; Nystatin; Vagina; Vaginal Diseases; Vaginitis; Vulva; Vulvar Diseases

Topics: Anti-Bacterial Agents; Candidiasis; Disease; Female; Humans; Nystatin; Pregnancy; Pregnancy Complications; Vagina; Vaginal Diseases

Topics: Anti-Bacterial Agents; Candida; Candida albicans; Candidiasis; Disease; Female; Humans; Incidence; Nystatin; Vagina; Vaginal Diseases; Vaginitis; Vulva; Vulvar Diseases

Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Candidiasis; Candidiasis, Vulvovaginal; Disease; Female; Humans; Intestines; Nystatin; Vagina; Vaginal Diseases